Global Urethral Bulking Systems Market
Global Urethral Bulking Systems Market

Urethral Bulking Systems Comprehensive Study by Treatment (Endoscopic, Non-Endoscopic), Indication (Stress Urinary Incontinence, Urgency Urinary Incontinence, Other Urinary Deficiency), End Use (Hospitals, Specialty Clinics, Ambulatory Surgical Centers) Players and Region - Global Market Outlook to 2026

Urethral Bulking Systems Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 240 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Urethral Bulking Systems Market Scope
Involuntary loss of urine during a period of elevated abdominal pressure and in the absence of detrusor activity is known as stress urinary incontinence (SUI). Bulking drugs administered in the urethra are a relatively new but well-established therapeutic option for SUI. Understanding the demographics of SUI can aid in the selection of patients who will benefit from bulking agent therapy. In women, urethral thickening is normally performed under local anaesthetic, whereas men may require general or regional anaesthesia. After an injection, a local anaesthetic lets the person to get up to see if continence has been attained.

The Urethral Bulking Systems market study is segmented and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Urethral Bulking Systems market throughout the predicted period.

CR Bard (Becton, Dickinson and Company.) (United States), Merz Pharma GmbH & Co. KGaA (Germany), Cogentix Medical (Laborie, Inc.) (United States), Q-Med (Sweden), Ascentx Medical, Inc. (United States), Coloplast Corp (United States), Boston Scientific Corporation (United States) and AstraZeneca plc (United Kingdom) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Urethral Bulking Systems market by Type, Application and Region.

On the basis of geography, the market of Urethral Bulking Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies

On 28th January, 2020 - Contura International A/S Received US FDA Approval for its Application for Bulkamid Urethral Bulking System - P170023. Bulkamid is a Thick, Lasting Gel Is Used for Treatment of Stress Urine Incontinence in Women Who Have Weak Pelvic Floor Muscles (Urethral Sphincter).


Market Trend
  • Rising Geriatric Population

Market Drivers
  • Prevalence of Stress Urinary Incontinence (SUI)
  • Growing Healthcare Awareness

Opportunities
  • High Investment in Healthcare R&D
  • Growing Medical Infrastructure Across Emerging Regions

Restraints
  • Lack of Expertise

Challenges
  • Fierce Competitive Pressure


Key Target Audience
Urethral Bulking Systems Manufactures, New Entrants and Investors, Urethral Bulking Systems Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Urethral Bulking Systems Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Treatment
  • Endoscopic
  • Non-Endoscopic

By Indication
  • Stress Urinary Incontinence
  • Urgency Urinary Incontinence
  • Other Urinary Deficiency

By End Use
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Stress Urinary Incontinence (SUI)
      • 3.2.2. Growing Healthcare Awareness
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. Rising Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Urethral Bulking Systems, by Treatment, Indication, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Urethral Bulking Systems (Value)
      • 5.2.1. Global Urethral Bulking Systems by: Treatment (Value)
        • 5.2.1.1. Endoscopic
        • 5.2.1.2. Non-Endoscopic
      • 5.2.2. Global Urethral Bulking Systems by: Indication (Value)
        • 5.2.2.1. Stress Urinary Incontinence
        • 5.2.2.2. Urgency Urinary Incontinence
        • 5.2.2.3. Other Urinary Deficiency
      • 5.2.3. Global Urethral Bulking Systems by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
        • 5.2.3.3. Ambulatory Surgical Centers
      • 5.2.4. Global Urethral Bulking Systems Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Urethral Bulking Systems: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CR Bard (Becton, Dickinson and Company.) (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merz Pharma GmbH & Co. KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cogentix Medical (Laborie, Inc.) (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Q-Med (Sweden)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ascentx Medical, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Coloplast Corp (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Boston Scientific Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Urethral Bulking Systems Sale, by Treatment, Indication, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Urethral Bulking Systems (Value)
      • 7.2.1. Global Urethral Bulking Systems by: Treatment (Value)
        • 7.2.1.1. Endoscopic
        • 7.2.1.2. Non-Endoscopic
      • 7.2.2. Global Urethral Bulking Systems by: Indication (Value)
        • 7.2.2.1. Stress Urinary Incontinence
        • 7.2.2.2. Urgency Urinary Incontinence
        • 7.2.2.3. Other Urinary Deficiency
      • 7.2.3. Global Urethral Bulking Systems by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
        • 7.2.3.3. Ambulatory Surgical Centers
      • 7.2.4. Global Urethral Bulking Systems Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Urethral Bulking Systems: by Treatment(USD Million)
  • Table 2. Urethral Bulking Systems Endoscopic , by Region USD Million (2015-2020)
  • Table 3. Urethral Bulking Systems Non-Endoscopic , by Region USD Million (2015-2020)
  • Table 4. Urethral Bulking Systems: by Indication(USD Million)
  • Table 5. Urethral Bulking Systems Stress Urinary Incontinence , by Region USD Million (2015-2020)
  • Table 6. Urethral Bulking Systems Urgency Urinary Incontinence , by Region USD Million (2015-2020)
  • Table 7. Urethral Bulking Systems Other Urinary Deficiency , by Region USD Million (2015-2020)
  • Table 8. Urethral Bulking Systems: by End Use(USD Million)
  • Table 9. Urethral Bulking Systems Hospitals , by Region USD Million (2015-2020)
  • Table 10. Urethral Bulking Systems Specialty Clinics , by Region USD Million (2015-2020)
  • Table 11. Urethral Bulking Systems Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 12. South America Urethral Bulking Systems, by Country USD Million (2015-2020)
  • Table 13. South America Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 14. South America Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 15. South America Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 16. Brazil Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 17. Brazil Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 18. Brazil Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 19. Argentina Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 20. Argentina Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 21. Argentina Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 22. Rest of South America Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 23. Rest of South America Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 24. Rest of South America Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 25. Asia Pacific Urethral Bulking Systems, by Country USD Million (2015-2020)
  • Table 26. Asia Pacific Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 27. Asia Pacific Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 28. Asia Pacific Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 29. China Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 30. China Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 31. China Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 32. Japan Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 33. Japan Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 34. Japan Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 35. India Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 36. India Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 37. India Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 38. South Korea Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 39. South Korea Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 40. South Korea Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 41. Taiwan Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 42. Taiwan Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 43. Taiwan Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 44. Australia Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 45. Australia Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 46. Australia Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 50. Europe Urethral Bulking Systems, by Country USD Million (2015-2020)
  • Table 51. Europe Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 52. Europe Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 53. Europe Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 54. Germany Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 55. Germany Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 56. Germany Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 57. France Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 58. France Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 59. France Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 60. Italy Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 61. Italy Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 62. Italy Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 63. United Kingdom Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 64. United Kingdom Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 65. United Kingdom Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 66. Netherlands Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 67. Netherlands Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 68. Netherlands Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 69. Rest of Europe Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 70. Rest of Europe Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 71. Rest of Europe Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 72. MEA Urethral Bulking Systems, by Country USD Million (2015-2020)
  • Table 73. MEA Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 74. MEA Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 75. MEA Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 76. Middle East Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 77. Middle East Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 78. Middle East Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 79. Africa Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 80. Africa Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 81. Africa Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 82. North America Urethral Bulking Systems, by Country USD Million (2015-2020)
  • Table 83. North America Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 84. North America Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 85. North America Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 86. United States Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 87. United States Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 88. United States Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 89. Canada Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 90. Canada Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 91. Canada Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 92. Mexico Urethral Bulking Systems, by Treatment USD Million (2015-2020)
  • Table 93. Mexico Urethral Bulking Systems, by Indication USD Million (2015-2020)
  • Table 94. Mexico Urethral Bulking Systems, by End Use USD Million (2015-2020)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Urethral Bulking Systems: by Treatment(USD Million)
  • Table 104. Urethral Bulking Systems Endoscopic , by Region USD Million (2021-2026)
  • Table 105. Urethral Bulking Systems Non-Endoscopic , by Region USD Million (2021-2026)
  • Table 106. Urethral Bulking Systems: by Indication(USD Million)
  • Table 107. Urethral Bulking Systems Stress Urinary Incontinence , by Region USD Million (2021-2026)
  • Table 108. Urethral Bulking Systems Urgency Urinary Incontinence , by Region USD Million (2021-2026)
  • Table 109. Urethral Bulking Systems Other Urinary Deficiency , by Region USD Million (2021-2026)
  • Table 110. Urethral Bulking Systems: by End Use(USD Million)
  • Table 111. Urethral Bulking Systems Hospitals , by Region USD Million (2021-2026)
  • Table 112. Urethral Bulking Systems Specialty Clinics , by Region USD Million (2021-2026)
  • Table 113. Urethral Bulking Systems Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 114. South America Urethral Bulking Systems, by Country USD Million (2021-2026)
  • Table 115. South America Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 116. South America Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 117. South America Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 118. Brazil Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 119. Brazil Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 120. Brazil Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 121. Argentina Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 122. Argentina Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 123. Argentina Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 124. Rest of South America Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 125. Rest of South America Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 126. Rest of South America Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 127. Asia Pacific Urethral Bulking Systems, by Country USD Million (2021-2026)
  • Table 128. Asia Pacific Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 129. Asia Pacific Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 130. Asia Pacific Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 131. China Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 132. China Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 133. China Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 134. Japan Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 135. Japan Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 136. Japan Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 137. India Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 138. India Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 139. India Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 140. South Korea Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 141. South Korea Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 142. South Korea Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 143. Taiwan Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 144. Taiwan Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 145. Taiwan Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 146. Australia Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 147. Australia Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 148. Australia Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 152. Europe Urethral Bulking Systems, by Country USD Million (2021-2026)
  • Table 153. Europe Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 154. Europe Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 155. Europe Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 156. Germany Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 157. Germany Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 158. Germany Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 159. France Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 160. France Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 161. France Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 162. Italy Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 163. Italy Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 164. Italy Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 165. United Kingdom Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 166. United Kingdom Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 167. United Kingdom Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 168. Netherlands Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 169. Netherlands Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 170. Netherlands Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 171. Rest of Europe Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 172. Rest of Europe Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 173. Rest of Europe Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 174. MEA Urethral Bulking Systems, by Country USD Million (2021-2026)
  • Table 175. MEA Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 176. MEA Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 177. MEA Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 178. Middle East Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 179. Middle East Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 180. Middle East Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 181. Africa Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 182. Africa Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 183. Africa Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 184. North America Urethral Bulking Systems, by Country USD Million (2021-2026)
  • Table 185. North America Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 186. North America Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 187. North America Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 188. United States Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 189. United States Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 190. United States Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 191. Canada Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 192. Canada Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 193. Canada Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 194. Mexico Urethral Bulking Systems, by Treatment USD Million (2021-2026)
  • Table 195. Mexico Urethral Bulking Systems, by Indication USD Million (2021-2026)
  • Table 196. Mexico Urethral Bulking Systems, by End Use USD Million (2021-2026)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Urethral Bulking Systems: by Treatment USD Million (2015-2020)
  • Figure 5. Global Urethral Bulking Systems: by Indication USD Million (2015-2020)
  • Figure 6. Global Urethral Bulking Systems: by End Use USD Million (2015-2020)
  • Figure 7. South America Urethral Bulking Systems Share (%), by Country
  • Figure 8. Asia Pacific Urethral Bulking Systems Share (%), by Country
  • Figure 9. Europe Urethral Bulking Systems Share (%), by Country
  • Figure 10. MEA Urethral Bulking Systems Share (%), by Country
  • Figure 11. North America Urethral Bulking Systems Share (%), by Country
  • Figure 12. Global Urethral Bulking Systems share by Players 2020 (%)
  • Figure 13. Global Urethral Bulking Systems share by Players (Top 3) 2020(%)
  • Figure 14. Global Urethral Bulking Systems share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. CR Bard (Becton, Dickinson and Company.) (United States) Revenue, Net Income and Gross profit
  • Figure 17. CR Bard (Becton, Dickinson and Company.) (United States) Revenue: by Geography 2020
  • Figure 18. Merz Pharma GmbH & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merz Pharma GmbH & Co. KGaA (Germany) Revenue: by Geography 2020
  • Figure 20. Cogentix Medical (Laborie, Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 21. Cogentix Medical (Laborie, Inc.) (United States) Revenue: by Geography 2020
  • Figure 22. Q-Med (Sweden) Revenue, Net Income and Gross profit
  • Figure 23. Q-Med (Sweden) Revenue: by Geography 2020
  • Figure 24. Ascentx Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Ascentx Medical, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Coloplast Corp (United States) Revenue, Net Income and Gross profit
  • Figure 27. Coloplast Corp (United States) Revenue: by Geography 2020
  • Figure 28. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. Boston Scientific Corporation (United States) Revenue: by Geography 2020
  • Figure 30. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 32. Global Urethral Bulking Systems: by Treatment USD Million (2021-2026)
  • Figure 33. Global Urethral Bulking Systems: by Indication USD Million (2021-2026)
  • Figure 34. Global Urethral Bulking Systems: by End Use USD Million (2021-2026)
  • Figure 35. South America Urethral Bulking Systems Share (%), by Country
  • Figure 36. Asia Pacific Urethral Bulking Systems Share (%), by Country
  • Figure 37. Europe Urethral Bulking Systems Share (%), by Country
  • Figure 38. MEA Urethral Bulking Systems Share (%), by Country
  • Figure 39. North America Urethral Bulking Systems Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • CR Bard (Becton, Dickinson and Company.) (United States)
  • Merz Pharma GmbH & Co. KGaA (Germany)
  • Cogentix Medical (Laborie, Inc.) (United States)
  • Q-Med (Sweden)
  • Ascentx Medical, Inc. (United States)
  • Coloplast Corp (United States)
  • Boston Scientific Corporation (United States)
  • AstraZeneca plc (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation